title: The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat.
abstract: The present study investigated the effect of fenofibrate, an agonist of PPAR-alpha, in nicotine- and sodium arsenite-induced vascular endothelial dysfunction (VED) in rats. Nicotine (2 mg/kg/day, i.p., 4 weeks) and sodium arsenite (1.5 mg/kg/day, i.p., 2 weeks) were administered to produce VED in rats. The scanning electron microscopy study in thoracic aorta revealed that administration of nicotine or sodium arsenite impaired the integrity of vascular endothelium. Further, administration of nicotine or sodium arsenite significantly decreased serum and aortic concentrations of nitrite/nitrate and subsequently reduced acetylcholine-induced endothelium-dependent relaxation. Moreover, nicotine or sodium arsenite produced oxidative stress by increasing serum thiobarbituric acid reactive substances (TBARS) and aortic superoxide generation. However, treatment with fenofibrate (30 mg/kg/day, p.o.) or atorvastatin (30 mg/kg/day p.o., a standard agent) significantly prevented nicotine- and sodium arsenite-induced VED and oxidative stress by improving the integrity of vascular endothelium, increasing the concentrations of serum and aortic nitrite/nitrate, enhancing the acetylcholine-induced endothelium-dependent relaxation and decreasing serum TBARS and aortic superoxide anion generation. Conversely, co-administration of L-NAME (25 mg/kg/day, i.p.), an inhibitor of nitric oxide synthase, markedly attenuated these vascular protective effects of fenofibrate. The administration of nicotine or sodium arsenite altered the lipid profile by increasing serum cholesterol and triglycerides and consequently decreasing high-density lipoprotein levels, which were significantly prevented by treatment with fenofibrate or atorvastatin. It may be concluded that fenofibrate improves the integrity and function of vascular endothelium, and the vascular protecting potential of fenofibrate in preventing the development of nicotine- and sodium arsenite-induced VED may be attributed to its additional properties (other than lipid lowering effect) such as activation of eNOS and generation of NO and consequent reduction in oxidative stress.
authors.affiliation: Pharmacology Division, ISF College of Pharmacy, Moga, 142 001, Punjab, India.
authors.forename: Jagdeep
authors.initials: J
authors.lastname: Kaur
authors.forename: Krishna
authors.initials: K
authors.lastname: Reddy
authors.forename: Pitchai
authors.initials: P
authors.lastname: Balakumar
mesh_terms: D000818:Animals; D018053:Arsenites / Q000037:antagonists & inhibitors / Q000633:toxicity*; D002784:Cholesterol / Q000097:blood; D004730:Endothelium, Vascular / Q000187:drug effects*; D011345:Fenofibrate / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D050356:Lipid Metabolism / Q000187:drug effects; D008075:Lipoproteins, HDL / Q000097:blood; D008855:Microscopy, Electron, Scanning; D009538:Nicotine / Q000633:toxicity*; D018733:Nicotinic Antagonists; D009566:Nitrates / Q000378:metabolism; D009573:Nitrites / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D017670:Sodium Compounds / Q000037:antagonists & inhibitors / Q000633:toxicity*; D013481:Superoxides / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D014652:Vascular Diseases / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D018053:Arsenites; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D018733:Nicotinic Antagonists; D009566:Nitrates; D009573:Nitrites; D017670:Sodium Compounds; D017392:Thiobarbituric Acid Reactive Substances; D014280:Triglycerides; D013481:Superoxides; C017947:sodium arsenite; D009538:Nicotine; D002784:Cholesterol; D011345:Fenofibrate